XBP1 and breast carcinoma: Further, several studies investigated the therapeutic potentials of targeting Xbp1 and showed that aptamer-conjugated Xbp1 siRNA nanoparticles or scAAV2 vectors encoding the Xbp1 siRNAs could efficiently impair angiogenesis and suppress tumor growth in breast cancer [71–73].